Skip to main content
PLOS Neglected Tropical Diseases logoLink to PLOS Neglected Tropical Diseases
. 2021 Aug 2;15(8):e0009625. doi: 10.1371/journal.pntd.0009625

Modelling the ability of mass drug administration to interrupt soil-transmitted helminth transmission: Community-based deworming in Kenya as a case study

Nyuk Sian Chong 1,2, Stacey R Smith? 3,*, Marleen Werkman 2,4,5, Roy M Anderson 2,4
Editor: Guo-Jing Yang6
PMCID: PMC8360579  PMID: 34339450

Abstract

The World Health Organization has recommended the application of mass drug administration (MDA) in treating high prevalence neglected tropical diseases such as soil-transmitted helminths (STHs), schistosomiasis, lymphatic filariasis, onchocerciasis and trachoma. MDA—which is safe, effective and inexpensive—has been widely applied to eliminate or interrupt the transmission of STHs in particular and has been offered to people in endemic regions without requiring individual diagnosis. We propose two mathematical models to investigate the impact of MDA on the mean number of worms in both treated and untreated human subpopulations. By varying the efficay of drugs, initial conditions of the models, coverage and frequency of MDA (both annual and biannual), we examine the dynamic behaviour of both models and the possibility of interruption of transmission. Both models predict that the interruption of transmission is possible if the drug efficacy is sufficiently high, but STH infection remains endemic if the drug efficacy is sufficiently low. In between these two critical values, the two models produce different predictions. By applying an additional round of biannual and annual MDA, we find that interruption of transmission is likely to happen in both cases with lower drug efficacy. In order to interrupt the transmission of STH or eliminate the infection efficiently and effectively, it is crucial to identify the appropriate efficacy of drug, coverage, frequency, timing and number of rounds of MDA.

Author summary

We determine the best options for annual and biannual mass drug administration to control soil-transmitted helminths. An additional round of drugs can allow weaker drugs to be used. We apply the results to a community-based deworming project in Kenya.

Introduction

More than one billion people worldwide are affected by neglected tropical diseases (NTDs) every year [1]. High prevalence NTDs such as onchocerciasis, soil-transmitted helminths (STHs), schistosomiasis and lymphatic filariasis lock people into poverty even though they are amenable to periodic deworming via the use of anthelmintic medicines, also known as preventive chemotherapy (PC) [25]. The World Health Organization (WHO) [6] has introduced three strategies of applying PC in controlling STH infections:

  1. Mass drug administration (MDA), where PC is applied to the whole population of an endemic region at regular intervals, regardless of the infectious status of an individual.

  2. Targeted chemotherapy, where anthelmintic medicines are given to specific risk groups of people (e.g., specified by age and gender) at regular intervals, regardless of the infectious status of an individual.

  3. Selective chemotherapy, where anthelmintic medicines are given to infected individuals or individuals suspected to be infected.

In 2015, over 1.5 billion of doses of PC were administered to almost 1 billion individuals for at least one of the targeted infections: lymphatic filariasis, onchocerciasis, schistosomiasis, STHs and trachoma [4]. MDA strategies are not only safe and effective but also cost-effective in controlling these diseases [7, 8]; it costs between US $0.30 and US $0.50 per person treated in most settings [4]. To ensure the aim of MDA can be achieved successfully, improvements in water, sanitation and hygiene (WASH) infrastructure, hygiene education, training (such as planning, coordination, capacity building and data management and analysis) and human resources are crucial, including Social and Behaviour Change Communication (SBCC). Volunteers and experienced staff are needed to ensure that the drug-distribution strategy and implementation of MDA are carried out efficiently and effectively [4, 913].

The WHO recommends periodic MDA once a year if the prevalence of STH infections in the community is more than 20%—or twice a year if the prevalence exceeds 50%—in order to reduce the morbidity by reducing the worm burden [14]. To date, MDA, SBCC, WASH and hygiene education are the control strategies that have been widely implemented to reduce the rate of morbidity, especially in an endemic region with high prevalence of STH infections [911, 13, 1521]. In addition, MDA is usually carried out annually or biannually by delivering anthelmintic medicines to the at-risk population of an endemic area via school-based or community-based programmes. The WHO aims to eliminate and control STH infections through MDA strategies by covering at least 75% of preschool and school-age children [4, 6]. Nevertheless, different countries apply different types of strategies in conducting MDA programmes, depending on the local or national policies [2, 12, 20, 2224]. The WHO recommends a single dose of albendazole (400mg) or mebendazole (500mg) in MDA to treat soil-transmitted helminthiasis [25, 26]. Albendazole and mebendazole are highly effective in treating Ascaris lumbricoides and hookworm infections, but they are not as effective in treating Trichuris trichiura infection. The combination of albendazole and ivermectin is recommended for MDA of T. trichiura [22, 24, 2730].

By treating children in school, a higher treatment coverage can be achieved because school-aged children in untreated communities are the carriers of the highest burden of STHs and consequently suffer the greatest setbacks to growth, health and cognition during their development. Nevertheless, treating children alone does not always reduce the transmission significantly; this is especially the case for hookworm, as adults are the major drivers of transmission [31]. Although scaling up the treatment to the whole community will lead to significant reduction in transmission, the main issue is the cost of treatment, which depends on demography, coverage level, the population that is going to be treated and the frequency and duration of treatment. If the interruption of transmission does not happen from treating children alone, treatment has to be continued indefinitely unless WASH programmes, health education and SBCC can change the underlying conditions [31, 32].

A handful of authors have modelled MDA strategies to interrupt STH transmission. Anderson et al. [33] investigated the possibility of eliminating soil-transmitted helminthiasis if MDA is the only control strategy that has been taken. They discovered that the STH infection persists if MDA is only targeting pre-school-aged and school-aged children, except for the case where the reproduction number is low (R0 ≤ 2) and transmission intensity is low to medium. However, by considering WASH intervention, the value of R0 decreases significantly, and hence the high-transmission setting can be reduced to a medium or low one. In addition, their model showed that, with higher coverage of MDA, it is possible to interrupt the transmission of STHs if MDA is targeted at both children and adults. Clarke et al. [34] conducted a systematic review and meta-analysis (searching via MEDLINE, Embase and Web of Science for articles published on or before November 5, 2015) to compare the effect of mass (community-wide) and targeted (children only) strategies on STH prevalence in school-aged children. Both regression models and meta-analysis showed that the prevalence of STHs in children would be significantly reduced if mass MDA is performed compared to targeted MDA. Bronzan et al. [35] assessed the impact of community-based integrated MDA on schistosomiasis and STH prevalence in Togo. They observed that the prevalence of both schistosomiasis and STHs in children aged 6 to 9 are significantly reduced compared to the baseline. Moreover, they noticed that there is a resurgence of hookworm infection in children who are living in areas with high prevalence and who did not receive treatment in the past half year. Hence they suggested that areas with high prevalence should not only continue with the MDA strategy but also require environmental improvements such as improvements in WASH infrastructure and practices in order to interrupt the transmission of STHs. Truscott et al. [36] examined heterogeneity in transmission parameters that play a major role in hookworm infection using the baseline data obtained from the TUMIKIA study in Kenya (which was a large, randomised trial). This study showed that prevalence is related to the R0 value in a nonlinear manner (due to the effect of density-dependent fecundity) and that there is a clear increasing linear trend in mean R0 values versus mean egg count. Moreover, they observed that the prevalence depends highly on the degree of parasite aggregation. As a result, they suggested different MDA approaches should be carried out, especially when prevalence is low; when prevalence is sufficiently low, the high degree of parasite aggregation indicates that STHs may concentrate at the household level or in a group of people who consistently fail to comply with treatment or who consistently do not or cannot adopt improved WASH practices. Although MDA has been shown to be safe and effective in controlling STH infections, MDA alone has yet to be proven an effective long-term solution. Issues of potential anthelmintic resistance and donor fatigue in particular have raised concerns around long-term sustainability in controlling the transmission of STHs. Vaz Nery et al. [37] thus highlighted the need to study the application of WASH intervention and behaviour change to sustainably control long-term STH infection alongside the implementation of MDA in order to maintain low prevalence or achieve the global target of infection elimination.

Here, we would like to examine the impact of MDA on the mean number of worms in a human population and the possibility of interrupting the transmission of STHs if MDA is implemented. Two mathematical models are proposed in this study:

  1. an impulsive mean-worm model to examine the effect of MDA on the mean number of worms in a human population of size N;

  2. a modified form of the impulsive mean-worm model to examine the dynamics of the mean number of untreated worms due to lack of treatment or inefficacy of drug in the host population after the application of MDA.

This paper is organized as follows. First, we introduce our impulsive mathematical models and determine approximate analytical solutions. We then discuss the dynamics of the mean number of worms in host populations for community-based MDA of the TUMIKIA project in Kenya by applying both proposed models. We conclude with a discussion.

Mathematical models

A set of nonlinear ordinary differential equations depicting the dynamics of the approximate mean number of worms M(t) in a human population of size N (i.e., the total number of worms in a human population divided by N) and the infectious reservoir L(t) in the habitat of a human host at time t, proposed by Anderson and May [38], is defined as follows:

dMdt=βL-(μ+μ1)MdLdt=λ2ϕ(M;k,z)f(M;k,z)M-μ0Lλ2F(M;k,z)M-μ0L, (1)

where the associated parameters are defined in Table 1.

Table 1. Variables and parameters in model (1).

Variable/ Parameter Description
M(t) Mean number of worms in a human population of size N at time t
L(t) The infectious reservoir in the habitat of human host at time t
β The transmission rate between human and reservoir
μ 1 The human death rate
μ 0 The parasite mortality rate
μ The worm death rate
λ The within-host rate of egg production by female worms
k The clumping parameter of the negative binomial distribution
γ The strength of density-dependent effects on fecundity
z e γ

Since the observed pattern of worm numbers per host is well described empirically by a negative binomial distribution [38], the density-dependent constraints on adult worm fecundity can be described by

f(M;k,z)=[1+(1-z)Mk]-(k+1),

and the mating probability of adult worms is given by

ϕ(M;k,z)=1-[1+(1-z)Mk1+(2-z)M2k]k+1,

where k is the clumping parameter of the negative binomial distribution (where the degree of worm clumping is measured inversely by k), γ is the strength of density-dependent constraints, z = eγ measures the strength of the density-dependent effects on adult worm fecundity and F(M;k,z)ϕ(M;k,z)f(M;k,z). For a negative binomial probability distribution of worms per host, the prevalence of infection, y, is defined as

y=1-(1+Mk)-k.

By taking into account the fact that the lifespan of the infectious reservoir (about one month or less) is much shorter than the adult worm in the host (1–2 years), we expect the dynamics of L(t) will reach equilibrium much faster than the mean number of worms, M(t). We can thus rewrite model (1) as

dMdt=(μ+μ1)[R0F(M)-1]M, (2)

where R0=βλ2μ0(μ+μ1) is the reproduction number of this model in the absence of density-dependent effects in adult worm fecundity.

Clearly, M = 0 is an equilibrium point for model (2). Endemic equilibria, Meq, of model (2) exist whenever we solve R0F(Meq)-1=0. The numerical solution of Meq (using bisection method) is depicted in Fig 1. The stable solution of Meq is denoted by the solid line, whereas the unstable solution of Meq is represented by the dashed line. To avoid confusion, we denote the stable endemic equilibrium by M* and the unstable endemic equilibrium by M*. A bifurcation point, Mbp, exists in model (2) (denoted by the filled circle in Fig 1), defined as follows:

Mbp=k1-z{1-[2-z2(1-z)]k+1k+2}-1{[2(1-z)2-z]1k+2-1}.

Fig 1. Numerical solutions of the endemic equilibria Meq as a function of R0 with different k values, fixing z = 0.96.

Fig 1

The corresponding reproduction number of Mbp [38, 39] is given as follows:

R0bp={F(Mbp)}-1.

The aggregation of STH parasites in the human host population is one of the key parameters in determining the prevalence of infection, y. Fig 1 shows that the endemic equilibrium and breakpoint of model (2) become smaller whenever k is decreasing. In this case, we may have fewer individuals in the population who carry a higher burden of parasites if the probability distribution of STH parasites within the human host population becomes highly aggregated (i.e., when k is small).

Next, we investigate the stability of the equilibrium point of model (2). An equilibrium occurs when there is no change in the rate of change of M, and the stability of an equilibrium point describes the effect of small perturbations near the equilibrium. If small deviations return to the equilibrium (or remain close), then the equilibrium is stable and is hence robust to noise and other random factors; if the equilibrium is unstable, then even very small perturbations will deviate from it over time. Since model (2) is one-dimensional, the stability of the equilibrium is determined by the sign of the derivative at the equilibrium.

Theorem. Let Meq represent the endemic equilibrium of model(2). The disease-free equilibrium of model(2)is always locally asymptotically stable. The endemic equilibrium of model(2)is locally asymptotically stable if Meq > Mbp and unstable if Meq < Mbp. A local bifurcation occurs at Mbp.

Proof. Differentiating model (2) with respect to M, we have

MM=(μ+μ1)[R0F(M)-1+R0F(M)M].

In the absence of infection, MM=-(μ+μ1)<0 since all associated parameters are positive. Hence the disease-free equilibrium (M = 0) of model (2) is locally asymptotically stable. Moreover, the endemic equilibrium of model (2) is locally asymptotically stable whenever

(μ+μ1)[R0F(Meq)-1+R0F(Meq)Meq]<01-zk{1-[2(1-z)2-z]-(k+1k+2)}Meq<[2(1-z)2-z]1k+2-1Meq>[2(1-z)2-z]1k+2-11-zk{1-[2(1-z)2-z]-(k+1k+2)}Mbp,

where [2(1-z)2-z]1k+2>11-[2(1-z)2-z]-(k+1k+2)<0, since all associated parameters are positive.

Therefore M* is locally asymptotically stable if Meq > Mbp (the infection will remain whenever the endemic equilibrium is larger than the breakpoint). Similarly, M* is unstable if Meq < Mbp. Moreover, a local bifurcation occurs at Mbp, where MM|M=Mbp=0. This completes the proof.

Thus a separatrix exists, which splits the phase portrait of this model into two regions: trajectories that start above this separatrix tend to M*, whereas trajectories with initial conditions below this separatrix will converge to M = 0.

A standard mean-worm model with impulsive effect

WHO-recommended MDA is one of the most effective treatments to combat STH infection in endemic regions, and it is used to prevent morbidity caused by STH infection. By treating worms, the morbidity of STH can be reduced [15, 25, 38, 4042]. We thus examine the impact of MDA on the dynamics of the mean number of worms in a human population of size N by adding an impulsive effect into model (2). Hence our impulsive model, one that is governed by a set of impulsive differential equations, is defined as follows:

dMdt=(μ+μ1)[R0F(M)-1]Mttn (3)
M(tn+)=(1-ωϵ)M(tn-)t=tn, (4)

where tn is the time when MDA is implemented, n is an arbitrary positive integer, ω is the coverage of MDA and ϵ is the efficacy of drug. Impulsive differential equations generally lead to semi-continuous periodic orbits whose endpoints describe the local maxima and minima during each cycle. The endpoints of the impulsive orbit at time t = tn are M(tn-) and M(tn+), where M(tn-) is the mean number of worms in a human population immediately before applying MDA, while M(tn+) is the mean number of worms immediately after applying MDA.

Throughout this manuscript, we choose z = 0.96, μ = 0.5 per year and μ1=175 per year in performing the numerical simulations, unless otherwise stated. To examine the impact of MDA, numerical simulations that consider the application of one round of MDA at time t = 1 versus no treatment are compared, and the results are shown in Fig 2. For arbitrary k, ω and ϵ values, all trajectories of model (3) and (4) as in Fig 2a and 2b are converging to zero if M0, the initial value of M, is below the unstable endemic equilibrium M*. However, with the application of one round of MDA at t = 1 (black and red solid curves), elimination of STH transmission can be achieved faster if ω and ϵ are sufficiently high compared to no treatment (blue solid curve). For sufficiently large M0 (i.e., M0 = M* as in Fig 2e and 2f), all solutions eventually approach the stable endemic equilibrium M*, but trajectories with higher ω and ϵ values (red solid curves) take the longest time to reach M*. This shows that the control strategy has reduced the mean number of worms and prolonged the time for the disease to achieve its endemic steady state. In addition, for arbitrary M* < M0 < M*, eradication is possible if we could successfully interrupt the transmission (for instance, by applying treatment) and reduce the mean number of worms such that it is less than M* (see Fig 2c and 2d). Hence the solution of model (2) will converge to zero, and interruption of transmission is likely. Therefore, in order to achieve the target of transmission interruption, the application of the control strategy is crucial when the mean number of worms is greater than the transmission breakpoint, M*.

Fig 2. Transmission dynamics of model (3) and (4) considering no application of MDA and one round of MDA at time t = 1 with k = 0.05 and R0 = 2.

Fig 2

(a) M0 < M*. (b) M* < M0 < M*. (c) M0 = M*. (d) M0 > M*.

Next, we examine the effect of applying biannual and annual MDA on STH transmission. By varying ϵ while selecting ω = 0.5, R0 = 2 and M* < M0 < M* in Fig 3, treatment is again unnecessary if M < M*. From Fig 3, we observe that, for k = 0.05, six and three rounds of biannual MDA (respectively, seven and three rounds of annual MDA) are needed in order to eliminate STH infection if the efficacies of drug are 0.4 (i.e., 40% of the mean number of worms in the human population are removed if MDA is taken) and 0.8, respectively. Conversely, for k = 0.5, eight and three rounds of biannual MDA (respectively, eleven and four rounds of annual MDA) are required, with the aim of disease eradication, if ϵ = 0.4 and 0.8, respectively. These results show that more rounds of MDA are needed to eradicate the disease if k is large, the drug efficacy is low and MDA is applied less frequently. The value of M* varies greatly if k and R0 values are increasing, but the value of M* does not vary much in this case, as shown in Fig 1.

Fig 3. Transmission dynamics of model (3) and (4) by considering the implementation of biannual and annual MDA, M0 > M*, varying ϵ and choosing z = 0.96, R0 = 2 and ω = 0.5.

Fig 3

Top row: biannual MDA. Bottom row: annual MDA. Left column: k = 0.05. Right column: k = 0.5.

Overestimates

We have shown that the STH infection will eventually decline (even without treatment) if M < M*. Thus we examine the case M0 > M* by using an overestimate of model (3) and (4) to estimate the number of rounds of MDA required to reduce the mean number of worms to less than the transmission breakpoint and hence interrupt STH transmission.

For arbitrary M(t)>M* and ttn such that t(tn-1+,tn-), Eq (3) is bounded by

dMdt(μ+μ1)(R0Fmax-1)M,whereFmax=F(Mbp).

Hence, for arbitrary t(tn-1+,tn-) and M(t)>M*, the solution of (3) is bounded by

M(tn-)M(tn-1+)e(μ+μ1)(R0Fmax-1)Δt, (5)

where the mean number of worms in a human population of density N decays exponentially if R0Fmax<1 (respectively, grows if R0Fmax>1). After undergoing an impulse, the solution is bounded by

M(tn+)(1-ωϵ)M(tn-1+)e(μ+μ1)(R0Fmax-1)Δt, (6)

where Δt = tntn−1 is assumed fixed in our study since the MDA is usually applied at fixed intervals.

By considering F(M)Fmax for arbitrary M, we expect that the analytical solution (5) with (6) may overestimate the solution of model (3) and (4). Thus, to determine whether (5) and (6) provide a good approximation to the solution of model (3) and (4), we compare these two solutions for arbitrary M(t)>M* by taking into consideration both biannual and annual MDA control strategies in Figs 4 and 5, respectively. Moreover, by choosing ω = 0.5, ϵ = 0.4 and varying k and R0 values, the mean squared error (MSE) of these two solutions can be used to identify the magnitude of differences between these two solutions. Given any two functions, g1(ti) and g2(ti), where i = 0, 1, 2, …, m − 1, the MSE is defined as follows [43, 44]:

MSE=1mi=0m-1[g2(ti)-g1(ti)]2.
Fig 4. The comparison of the overestimate (5) and (6) and original model (3) and (4) by considering the implementation of biannual MDA with ϵ = 0.4 and ω = 0.5 and varying k and R0 values.

Fig 4

(a) R0 = 2, k = 0.05, n > 5.83 and MSE = 0.1258 × 10−4. (b) R0 = 2, k = 0.5, n > 8.34 and MSE = 0.2167 × 10−2. (c) R0 = 1.8, k = 0.05, n > 2.86 and MSE = 0.5217 × 10−6. (d) R0 = 1.8, k = 0.5, n > 5.38 and MSE = 0.6392 × 10−3.

Fig 5. The comparison of solutions (5) and (6) and numerical solutions of model (3) and (4) by considering the implementation of annual MDA with ϵ = 0.4 and ω = 0.5 and varying k and R0 values.

Fig 5

(a) R0 = 2, k = 0.05, n > 7.29 and MSE = 0.6333 × 10−4. (b) R0 = 2, k = 0.5, n > 13.14 and MSE = 0.0156. (c) R0 = 1.8, k = 0.05, n > 2.96 and MSE = 0.2106 × 10−5. (d) R0 = 1.8, k = 0.5, n > 6.29 and MSE = 0.2264 × 10−2.

To find the endpoints of an impulsive orbit, first let us suppose that M(t0+)=M0. Then we obtain

M(t1-)M0e(μ+μ1)(R0Fmax-1)ΔtM(t1+)(1-ωϵ)M0e(μ+μ1)(R0Fmax-1)ΔtM(t2-)(1-ωϵ)M0e2(μ+μ1)(R0Fmax-1)ΔtM(t2+)(1-ωϵ)2M0e2(μ+μ1)(R0Fmax-1)ΔtM(tn-)(1-ωϵ)n-1M0en(μ+μ1)(R0Fmax-1)ΔtM(t1+)(1-ωϵ)nM0en(μ+μ1)(R0Fmax-1)Δt.

The impulsive orbit is bounded above by an orbit with endpoints

(1-ωϵ)n-1M0en(μ+μ1)(R0Fmax-1)Δtand(1-ωϵ)nM0en(μ+μ1)(R0Fmax-1)Δt.

Knowing the endpoints, we are able to find the estimated number of rounds of MDA such that M(tn+)<M* with fixed ω and ϵ; i.e.,

n>ln(M*M0)ln(1-ωϵ)+(μ+μ1)(R0Fmax-1)Δt, (7)

or with fixed n (and ϵ or ω), the estimated values of ω and ϵ such that disease elimination is possible are given by

ω>1ϵ[1-(M*M0)1ne-(μ+μ1)(R0Fmax-1)Δt]

and

ϵ>1ω[1-(M*M0)1ne-(μ+μ1)(R0Fmax-1)Δt],

respectively.

From Figs 4 and 5, we discover that numerical solutions of both the overestimate (5) and (6) and the original model (3) and (4) are compatible if k and R0 values are sufficiently small. Moreover, both solutions have a better agreement for the case study of biannual MDA compared to annual MDA, where we can see that the MSE values for the biannual MDA are smaller than the annual MDA for arbitrary initial conditions, k and R0 values. Using Eq (7), the estimated number of rounds of biannual MDA such that interruption of STH transmission is feasible is well-matched with the numerical prediction for arbitrary k and R0 values, but it only has good agreement if k and R0 values are sufficiently small for annual MDA.

A modified form of the impulsive mean worm model

In this section, we examine the behaviour of the mean number of untreated worms due to no treatment as well as inefficacy of drug in the host population after the application of MDA. Suppose that the mean number of worms in a human population of size N before the application of any control strategy is M. By applying MDA, the human population of size N can be divided into two subpopulations: treated and untreated, denoted Nt and Nnt, respectively.

Next, assume that there are ωN treated people and (1 − ω)N untreated people, where ω is the coverage of MDA, and the total human population is N = Nt + Nnt. Let Mt represent the mean number of untreated worms due to inefficacy of drug in the treated population and Mnt represent the mean number of worms in the untreated population. For ttn, the dynamics of Mnt(t), Mt(t) and L(t) can be described by the following differential equations:

dMntdt=βL-(μ+μ1)MntttndMtdt=βL-(μ+μ1)MtttndLdt=λ2[(1-ω)F(Mnt)Mnt+ωF(Mt)Mt]-μ0Lttn. (8)

Since the lifespan of adult worms in human hosts is much longer than the lifespan of larvae or eggs, the rate of change of L(t) is expected to move much faster than Mnt and Mt; hence we can rewrite model (8) using the equilibrium state of L as follows:

dMntdt=(μ+μ1){R0[(1-ω)F(Mnt)Mnt+ωF(Mt)Mt]-Mnt}ttndMtdt=(μ+μ1){R0[(1-ω)F(Mnt)Mnt+ωF(Mt)Mt]-Mt}ttn, (9)

with impulse conditions

Mnt(tn+)=Mnt(tn-)t=tnMt(tn+)=(1-ϵ)Mt(tn-)t=tn. (10)

The disease-free equilibrium for model (9) is (Mnt, Mt) = (0, 0), and the endemic equilibrium is M^=(Mnt,Mt)=(Mnt*,Mnt*)=(Mt*,Mt*), since Mnt*=Mt*. Mt* can be found by solving R0F(Mt*)-1=0 numerically, similar to the result obtained in Fig 1.

Theorem. The disease-free equilibrium of model(9)is always locally asymptotically stable. The endemic equilibrium of model(9)is locally asymptotically stable ifR0<1F(Mt*)+Mt*F(Mt*)and unstable ifR0>1F(Mt*)+Mt*F(Mt*).

Proof. Let λ^ represent the eigenvalue of model (9). Then the characteristic equation is

λ^2+(μ+μ1){2-R0(1-ω)[F(Mnt)+MntF(Mnt)]-R0ω[F(Mt)+MtF(Mt)]}λ^+(μ+μ1)2{1-R0(1-ω)[F(Mnt)+MntF(Mnt)]-R0ω[F(Mt)+MtF(Mt)]}=0.

In the absence of infection, λ^0=-(μ+μ1)<0 with multiplicity 2, since all associated parameters are positive. Hence the DFE is locally asymptotically stable. For the endemic equilibrium, M^, we have

λ^1=-(μ+μ1)<0and
λ^2=(μ+μ1){R0[F(Mt*)+Mt*F(Mt*)]-1}<0ifR0<1F(Mt*)+Mt*F(Mt*).

Therefore M^ is locally asymptotically stable if R0<1F(Mt*)+Mt*F(Mt*). Otherwise, M^ is unstable. This completes the proof.

To avoid confusion, we denote the stable endemic equilibrium by M^*, the unstable endemic equilibrium by M^* and the initial value of (Mnt, Mt) by M^0.

When there is no implementation of any control strategy, we have Nt = 0 and N = Nnt. Thus the transmission dynamics of Mnt (model (9)) is similar to M (model (3)), which is illustrated in Fig 6 for arbitrary initial conditions. STH infection remains endemic whenever the initial values of M and Mnt are greater than the unstable equilibrium M* or M^* (in this case, these two models have similar equilibrium points; i.e., M*=M^* and M*=M^*); see Fig 6a and 6b. Conversely, disease elimination is always possible if M0 and Mnt0 are below the unstable equilibrium (see Fig 6c). We can thus infer that control strategies may not be necessary if M(t)<M* or Mnt(t)<M^*.

Fig 6. The comparison of models (3) and (9) when no control strategy has been applied.

Fig 6

Both models have the same outcomes for arbitrary initial points, R0 = 2 and k = 0.05. (a) M0 > M* and Mnt0>M^*. (b) M* < M0 < M* and M^*<Mnt0<M^*. (c) M0 < M* and Mnt0<M^*.

To investigate the impact of MDA in disease transmission, the transmission dynamics of Mnt and Mt with and without treatment are compared. By selecting k = 0.05, R0 = 2 and the implementation of MDA at t = 1, the transmission dynamics of model (9) with impulse (10) for arbitrary M^0>M^*, ω and ϵ is depicted in Fig 7. There is a decrease in the mean number of worms in both treated and untreated human subpopulations if treatment is taken compared to no application of MDA. However, if Mnt and Mt are still sufficiently large after treatment, this will increase the likelihood of disease spread, and hence STH infection will persist and remain endemic (see Fig 7a and 7b). The effects of ω and ϵ are more pronounced if M^0 is close to the neighbourhood of the unstable endemic equilibrium, M^*, in particular. From Fig 7c, we observe that disease elimination is likely to happen whenever ω and/or ϵ are sufficiently high, but STH infection persists if no control strategy is taken or if ω and ϵ are sufficiently low. Hence the application of MDA with appropriate ω and ϵ may hasten the elimination of STH infection.

Fig 7. The transmission dynamics of model (9) and (10) for a range of M^0>M^*, ϵ and ω values, with k = 0.05 and R0 = 2.

Fig 7

(a) ω = ϵ = 0.6 and M^*<M^0<M^*. (b) ω = ϵ = 0.6 and M^0>M^*. (c) M^0 around the neighbourhood of M^*.

Approximate analytical solution of (9) and (10)

In this subsection, we will focus on finding the approximate analytical solution of model (9) and (10) to estimate the required number of rounds of MDA in order to interrupt STH transmission for arbitrary M^0>M^*.

Eq (9) is bounded by

dMntdt(μ+μ1){[R0(1-ω)Fmax-1]Mnt+R0ωFmaxMt}dMtdt(μ+μ1)[R0(1-ω)FmaxMnt+(R0ωFmax-1)Mt]. (11)

Thus, for arbitrary t(tn-1+,tn-), the analytical solution of (11) satisfies

Mnt(tn-)[(1-ω)Mnt(tn-1+)+ωMt(tn-1+)]e(μ+μ1)(R0Fmax-1)Δt+ω[Mnt(tn-1+)-Mt(tn-1+)]e-(μ+μ1)ΔtMt(tn-)Mnt(tn-1+)+[Mt(tn-1+)-Mnt(tn-1+)]e-(μ+μ1)Δt, (12)

and, at impulse t = tn, by applying (10), we have

Mnt(tn+)[(1-ω)Mnt(tn-1+)+ωMt(tn-1+)]e(μ+μ1)(R0Fmax-1)Δt+ω[Mnt(tn-1+)-Mt(tn-1+)]e-(μ+μ1)ΔtMt(tn+)(1-ϵ){Mnt(tn-1+)+[Mt(tn-1+)-Mnt(tn-1+)]e-(μ+μ1)Δt}. (13)

We can compare numerical solutions of model (12) and (13) and model (9) and (10) with ω = ϵ = 0.6 and calculate the MSE to determine the magnitude of error between these two solutions. Fig 8 illustrates biannual MDA for both models, whereas Fig 9 compares annual MDA for these two solutions. By varying k and R0 values, the analytical and numerical solutions of Mnt and Mt in the case of biannual MDA demonstrate a better agreement compared to annual MDA. Moreover, we observe that analytical solutions forecast slightly higher values of Mnt and Mt and that more rounds of MDA are needed in order to achieve disease eradication compared to numerical solutions of model (9) and (10). This may be due to the approximations F(Mnt)Fmax and F(Mt)Fmax for arbitrary Mnt and Mt. Nevertheless, both analytical and numerical solutions of Mnt and Mt lead to a good agreement if k and R0 are sufficiently small and there is a higher frequency of MDA (biannual MDA in our case).

Fig 8. Numerical comparison of model (12) and (13) and model (9) and (10) by considering the implementation of biannual MDA with ϵ = ω = 0.6 and varying k and R0 values.

Fig 8

(a) k = 0.05, R0 = 1.8 and MSE for Mnt and Mt are 5.9377 × 10−5 and 1.1881 × 10−5, respectively. (b) k = 0.2, R0 = 1.8 and MSE for Mnt and Mt are 1.5909 × 10−3 and 2.2534 × 10−4, respectively. (c) k = 0.05, R0 = 2 and MSE for Mnt and Mt are 2.6274 × 10−4 and 2.9925 × 10−5, respectively. (d) k = 0.2, R0 = 2 and MSE for Mnt and Mt are 4.5018 × 10−3 and 4.7219 × 10−4, respectively.

Fig 9. Numerical comparison of model (12) and (13) and model (9) and (10) for annual MDA with ϵ = ω = 0.6 and varying k and R0 values.

Fig 9

(a) k = 0.05, R0 = 1.8 and MSE for Mnt and Mt are 1.4241 × 10−4 and 4.9371 × 10−5, respectively. (b) k = 0.2, R0 = 1.8 and MSE for Mnt and Mt are 3.2954 × 10−3 and 9.5671 × 10−4, respectively. (c) k = 0.05, R0 = 2 and MSE for Mnt and Mt are 4.3739 × 10−4 and 1.1943 × 10−4, respectively. (d) k = 0.2, R0 = 2 and MSE for Mnt and Mt are 8.6585 × 10−3 and 2.1309 × 10−3, respectively.

Applications to the TUMIKIA project in Kenya

The Global Atlas of Helminth Infections [45] reported that approximately 15 million Kenyans are infected with STHs. The TUMIKIA project has the objective to assess which strategy is more efficient and effective in both controlling and eliminating soil-transmitted helminthiasis in Kenya: the combination of school- and community-based MDA versus school-based MDA alone. There were 120 community clusters in Kwale County, Kenya, that had been selected to participate in this project over two years, and 40 community clusters had been randomized to take part in one of the following three strategies [4548]:

  1. Annual school-based MDA programme, involving pre-school and school-aged children.

  2. Annual community-based MDA programme, involving children and adults.

  3. Biannual community-based MDA programme.

In this section, we focus on the impact of TUMIKIA community-based biannual and annual deworming strategies on the dynamics of M, Mnt and Mt. A total of two (four) rounds of MDA had been implemented for a two-year community-based annual (biannual) MDA programme in Kenya. Moreover, the possibility of controlling STH infection in Kenya after the application of MDA for two years will be investigated. Model (3) and (4) will be employed to study the dynamics of M, whereas model (9) and (10) will be applied to study the dynamics of Mnt and Mt. Since approximately 15 million Kenyans are infected with STHs [45], out of an estimated 43 million Kenyans [49], the initial prevalence value of STH infection in Kenya is about 0.3488. Thus, the estimated k and R0 values are 0.1624 and 1.8, respectively [36]. By taking the average of ω for all community clusters that had participated in each round of biannual and annual MDA programmes, the numerical simulations of model (3) and (4) and model (9) and (10) are demonstrated in Figs 10 and 11. The overall mean number of worms in both treated and untreated human populations is given by

M¯=(1-ω)Mnt+ωMt.

Fig 10. Numerical results of model (3) and (4) and model (9) and (10) by varying ϵ and applying the coverage of MDA data from the TUMIKIA community-based biannual deworming control strategy.

Fig 10

(a) Disease persistence if ϵ < 0.44. (b) Disease extinction is possible if ϵ ≥ 0.61. (c) Disease extinction is possible for model (3) and (4) if ϵ ≥ 0.44, but the disease will remain in endemic state for model (9) and (10) if ϵ < 0.61.

Fig 11. The numerical results of model (3) and (4) and model (9) and (10) by varying ϵ and applying the coverage of MDA data from the TUMIKIA community-based annual deworming control strategy.

Fig 11

(a) Disease persistence if ϵ < 0.73. (b) Disease extinction if ϵ ≥ 0.85. (c) Disease elimination is possible for model (3) and (4) if ϵ ≥ 0.73, but the disease will remain in endemic state for model (9) and (10) if ϵ < 0.85.

From Fig 10, we see that, by implementing the TUMIKIA community-based biannual MDA strategy for two years, STH infection remains endemic for both models (3) and (4) and (9) and (10) if ϵ < 0.44, but the infection dies off if ϵ ≥ 0.61 (see Fig 10a and 10b, respectively). However, Fig 10c shows that multiple outcomes are possible, depending on the model. That is, model (3) and (4) predicts interruption of transmission is possible if ϵ ≥ 0.44, but model (9) and (10) forecasts that STH infection persists if ϵ < 0.61. By considering an additional round of TUMIKIA community-based biannual MDA at time t = 2.5 or t = 7, where the coverage of MDA is increased to 0.72, we notice that, in Fig 12, interruption of STH transmission is possible even though ϵ = 0.44.

Fig 12. Numerical solutions of model (9) and (10) with an additional round of TUMIKIA community-based biannual deworming strategy.

Fig 12

For the TUMIKIA community-based annual MDA strategy, we notice that in Fig 11a and 11b, both models predict disease persistence whenever ϵ < 0.73 and disease extinction if ϵ ≥ 0.85, respectively. Nevertheless, we can see that there are multiple possible outcomes in Fig 11c: model (3) and (4) forecasts disease eradication if ϵ ≥ 0.73, but model (9) and (10) predicts that disease eradication is unlikely if ϵ < 0.85.

From Fig 11, we observe that a sufficiently high efficacy of drug is needed (ϵ ≥ 0.85) in order to eliminate STH infection for the TUMIKIA community-based annual MDA programme using model (9) and (10). Thus we investigated the possibility of transmission interruption by considering the application of an additional round of MDA. Two cases are examined: an additional round of MDA is employed in the third and seventh years after the last round of TUMIKIA community-based annual deworming (i.e., at times t = 3 and 7, respectively) with coverage ω = 0.6. From Fig 13, we see that the STH infection in both cases will decline if ϵ ≥ 0.77. However, the infection is eliminated faster than in Fig 11. Since the rates of change of Mnt and Mt are very small around the unstable endemic equilibrium M^*, the interruption of STH infection in Fig 11 takes a long time to reach a disease-free state. Hence it is crucial for us to assess the appropriate coverage of MDA, efficacy of the drug and timing of the deworming strategy if we aim to achieve interruption of transmission quickly and effectively.

Fig 13. Numerical solutions of model (9) and (10) with an additional round of TUMIKIA community-based annual deworming strategy.

Fig 13

Discussion

To examine the impact of MDA on the dynamics of STH infection in host populations and the feasibility of interrupting the transmission, two novel impulsive mathematical models were proposed: 1) a standard mean-worm model (3) and (4) to describe the effect of deworming strategy on the mean number of worms in a host population of size N, and 2) a modified form of the standard mean-worm model (9) and (10) to describe the dynamics of the mean number of worms in treated and untreated human subpopulations undergoing MDA.

Both models forecast that the application of MDA is unnecessary if the initial conditions are below the transmission breakpoint. If the initial number of worms is greater than the transmission breakpoint, then the mean number of worms in the host population can be suppressed using sufficient control strategies. Otherwise, there will be recrudescence in the community. Moreover, we found that fewer rounds of MDA are required to interrupt STH transmission if the clumping parameter (k) and basic reproduction number (R0) are sufficiently small or if the efficacy of drug, coverage and frequency of MDA are sufficiently high.

We also used both models to investigate worm dynamics for community-based MDA in the TUMIKIA project in Kenya. Both models predicted interruption of transmission was possible if the efficacy of drug was suffiently high (greater than 61% for the biannual programme or greater than 85% for the annual programme), whereas persistence was guaranteed if the efficacy was sufficiently low (less than 44% or 73%, respectively). The two models had different predictions when the efficacies were between these values. However, we showed that an additional round of MDA significantly improved the possibility of transmission interruption.

Our models have some limitations, which should be acknowledged. We set the infectious reservoir to steady state, due to the different timescales, although this may not apply perfectly. Impulsive differential equations assume the time-to-peak of MDA is negligible, which is only valid so long as the time between drug administrations is sufficiently large. STH eggs remain viable in soil for many years, so recrudescence of STH is inevitable without improvements in access to WASH and the adoption of new behaviours by the communities affected. We did not validate how long before STH recrudescence occurs if there is no WASH strategy or Social and Behaviour Change Communication. Finally, it is also crucial that the strategy implementation is respectful of the local context, traditional authorities, customs and belief systems.

Future work will consider age structure in human hosts, the effect of stochastic perturbations on disease transmission and assess the effectiveness of different potential interventions. We will also include a cost–benefit analysis of the MDA schedules. Implementing MDA programs takes time, coordination and costs, with volunteers increasingly expected to be paid for their services. More effective drugs delivered less frequently might be significantly cheaper for a health service than a cheaper drug requiring more rounds of MDA.

Acknowledgments

The authors are grateful to James Truscott and Robert Hardwick for fruitful discussions. For citation purpses, please note that the question mark in “Smith?” is part of her name. We extend our sincere thanks to the researchers who led data collection in Kenya during the TUMIKIA trial, including Paul M Gichuki, Stella Kepha, Carlos Mcharo, Stefan Witek-McManus, Mary W Karanja, Leah Musyoka, Lennie Mutisya, Tuva Safari, Idris Muye and Maureen Sidigu. Scientific oversight during data collection was provided by Charles Mwandawiro, Sammy Njenga and Simon Brooker. We also thank the many study participants who consented to provide stool samples, and the large study team, including managers, fieldworkers, laboratory technicians, and drivers. TUMIKIA was conducted in collaboration with the Government of Kenya Ministry of Health (MoH) and the Kwale County MoH. The views, opinions, assumptions or any other information set out in this article are solely those of the authors.

Data Availability

All relevant data are within the manuscript.

Funding Statement

NSC acknowledges support from the Ministry of Education of Malaysia and the Faculty of Ocean Engineering Technology and Informatics, Universiti Malaysia Terengganu. SS? is supported by an NSERC Discovery Grant and an NSERC Alliance Grant. RMA is grateful to the Bill and Melinda Gates Foundation for research grant support via the DeWorm3 (OPP1129535) award to the Natural History Museum in London (http://www.gatesfoundation.org/). NSC, MW and RMA acknowledge joint Centre funding from the UK Medical Research Council and Department for International Development. Funding for the TUMIKA project was received from the Bill & Melinda Gates Foundation, the Joint Global Health Trials Scheme of the Medical Research Council, the UK Department for International Development, the Wellcome Trust and the Children’s Investment Fund Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Kealey A. & Smith? R.J. 2010. Neglected Tropical Diseases: Infection, modeling & control. J Health Care Poor Underserved 21: 53–69. doi: 10.1353/hpu.0.0270 [DOI] [PubMed] [Google Scholar]
  • 2.de Souza D. K. & Dorlo T. P. C. 2018. Safe mass drug administration for neglected tropical diseases. The Lancet 6(10): 1054–1055. [DOI] [PubMed] [Google Scholar]
  • 3.Keenan J.D., Hotez P.J., Amza A., Stoller N.E., Gaynor B.D., Porco T.C. et al. 2013. Elimination and eradication of neglected tropical diseases with mass drug administrations: A survey of experts. PLoS Negl Trop Dis 7(12): e2562. doi: 10.1371/journal.pntd.0002562 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.World Health Organization. 2017. Crossing the billion. Lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminthiases and trachoma: preventive chemotherapy for neglected tropical diseases. Geneva: World Health Organization. Licence: CC BY-NC-SA 3.0 IGO. [Google Scholar]
  • 5.World Health Organization. 2019. Neglected tropical diseases. https://www.who.int/neglected_diseases/diseases/en/ Accessed December 6, 2019.
  • 6.World Health Organization. 2017. Guideline: Preventive chemotherapy to control soil-transmitted helminth infections in at-risk population groups. Geneva: World Health Organization. Licence: CC BY-NC-SA 3.0 IGO. [PubMed] [Google Scholar]
  • 7.Lo N.C., Andrews J.R. & Bogoch I.I. 2016. Improving helminth treatment access: costs and opportunities. The Lancet 16(7): 762–764. doi: 10.1016/S1473-3099(16)30049-4 [DOI] [PubMed] [Google Scholar]
  • 8.Turner H.C., Truscott J.E., Hollingsworth T.D., Bettis A.A., Brooker S.J. & Anderson R.M. 2015. Cost and cost-effectiveness of soil-transmitted helminth treatment programmes: systematic review and research needs. Parasites & Vectors 8: 355. doi: 10.1186/s13071-015-0885-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Ercumen A., Benjamin-Chung J., Arnold B.F., Lin A., Hubbard A.E., Stewart C., et al. 2019. Effects of water, sanitation, handwashing and nutritional interventions on soil-transmitted helminth infections in young children: a cluster-ransomized controlled trial in rural Bangladesh. PLoS Negl Trop Dis 13: e0007323. doi: 10.1371/journal.pntd.0007323 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Freeman M.C., Clasen T., Brooker S.J., Akoko D.O. & Rheingans R. 2013. The impact of a school-based hygiene, water quality and sanitation intervention on soil-transmitted helminth reinfection: a cluster-randomized trial. Am J Trop Med Hyg 89: 875–883. doi: 10.4269/ajtmh.13-0237 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Gyorkos T.W., Maheu-Giroux M., Blouin B. & Casapia M. 2013. Impact of health education on soil-transmitted helminth infections in schoolchildren of the Peruvian Amazon: a cluster-randomized controlled trial. PLoS Negl Trop Dis 7: e2397. doi: 10.1371/journal.pntd.0002397 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Neglected Tropical Diseases Support Center. 2018. Monitoring and supervising the annual mass drug administration for neglected tropical diseases in Ethiopia using a rapid coverage survey tool: A case study. https://www.ntdsupport.org/cor-ntd/blog/monitoring-and-supervising-annual-mass-drug-administration-neglected-tropical-diseases. Accessed December 6, 2019.
  • 13.Pickering A., Njenga S., Steinbaum L., Swarthout J., Lin A., Arnold B., et al. 2018. Effects of single and integrated water, sanitation, handwashing, and nutrition interventions on child soil-transmitted helminth and Giardia infections: A cluster-randomized controlled trial in rural Kenya. PLoS Med 16(6): e1002841. doi: 10.1371/journal.pmed.1002841 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.World Health Organization. 2021. Intestinal worms: Strategy. https://https://www.who.int/intestinal_worms/strategy/en/ Accessed March 29, 2021.
  • 15.Keiser J. & Utzinger J. 2019. Community-wide soil-transmitted helminth treatment is equity-effective. The Lancet 393: 2011–2012. doi: 10.1016/S0140-6736(18)32981-7 [DOI] [PubMed] [Google Scholar]
  • 16.Turner H.C., Truscott J.E., Fleming F.M., Hollingsworth T.D., Brooker S.J. & Anderson R.M. 2016. Cost-effectiveness of scaling up mass drug administration for the control of soil-transmitted helminths: a comparison of cost function and constant costs analyses. Lancet Infect Dis 16: 838–846. doi: 10.1016/S1473-3099(15)00268-6 [DOI] [PubMed] [Google Scholar]
  • 17.Anderson R.M. & Medley G.F. 1985. Community control of helminth infections of man by mass and selective chemotherapy. Parasitology 90: 629–660. doi: 10.1017/S0031182000052288 [DOI] [PubMed] [Google Scholar]
  • 18.Bah Y.M., Bah M.S., Paye J., Conteh A., Saffa S., Tia A., et al. 2019. Soil-transmitted helminth infection in school age children in Sierra Leone after a decade of preventive chemotherapy interventions. Infectious Diseases of Poverty 8: 41. doi: 10.1186/s40249-019-0553-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Dunn J.C., Bettis A.A., Wyine N.Y., Lwin A.M.M., Tun A., Maung N.S., et al. 2019. Soil-transmitted helminth reinfection four and six months after mass drug administration: results from the delta region of Myanmar. PLoS Negl Trop Dis 13(2): e0006591. doi: 10.1371/journal.pntd.0006591 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Farrell S.H., Coffeng L.E., Truscott J.E., Werkman M., Toor J., de Vlas S.J., et al. 2018. Investigating the effectiveness of current and modified World Health Organization guidelines for the control of soil-transmitted helminth infections. Clinical Infectious Diseases 66(S4): S253–259. doi: 10.1093/cid/ciy002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Truscott J.E., Werkman M., Wright J.E., Farrell S.H., Sarkar R., Ásbjörnsdóttir K.H., et al. 2017. Identifying optimal threshold statistics for elimination of hookworm using a stochastic simulation model. Parasites & Vectors 10: 321. doi: 10.1186/s13071-017-2256-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Hotez P.J. 2009. Mass drug administration and integrated control for the world’s high-prevalence neglected tropical diseases. Clinical Pharmacology & Therapeutics 85(6): 659–664. doi: 10.1038/clpt.2009.16 [DOI] [PubMed] [Google Scholar]
  • 23.United States Agency for International Development. 2019. Mass drug administration. https://neglecteddiseases.gov/about/what-we-do/mass-drug-administration Accessed December 6, 2019.
  • 24.Webster J.P., Molyneux D.H., Hotez P.J. & Fenwick A. 2014. The contribution of mass drug administration to global health: past, present and future. Phil. Trans. R. Soc. B 369: 20130434. doi: 10.1098/rstb.2013.0434 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.World Health Organization. 2021. Soil-transmitted helminth infections. https://www.who.int/news-room/fact-sheets/detail/soil-transmitted-helminth-infections Accessed March 25, 2021.
  • 26.World Health Organization. 2019. Deworming in children. https://www.who.int/elena/titles/guidance_summaries/deworming-children/en/ Accessed December 6, 2019.
  • 27.Adegnika A.A., Lötsch F., Mba R.M.O. & Ramharter M. 2015. Update on treatment and resistance of human trichuriasis. Curr Trop Med Rep 2: 218–223. doi: 10.1007/s40475-015-0061-z [DOI] [Google Scholar]
  • 28.Patel C., Hürlimann E., Keller L., Hattendorf J., Sayasone S., Ali et al. 2019. Efficacy and safety of ivermectin and albendazole co-administration in school-aged children and adults infected with Trichuris trichiura: study protocol for a multi-country randomized controlled double-blind trial. BMC Infectious Diseases 19: 262. doi: 10.1186/s12879-019-3882-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Speich B., Ali S.M., Ame S.M., Bogoch I.I., Alles R., Huwyler J., et al. 2015. Efficacy and safety of albendazole plus ivermectin, albendazole plus mebendazole, albendazole plus oxantel pamoate, and mebendazole alone against Trichuris trichiura and concomitant soil-transmitted helminth infections: a four-arm, randomised controlled trial. The Lancet 15: 277–284. [DOI] [PubMed] [Google Scholar]
  • 30.Speich B., Moser W., Ali S.M., Ame S.M., Albonico M., Hattendori J., et al. 2016. Efficacy and reinfection with soil-transmitted helminths 18-weeks post-treatment with albendazole-ivermectin, albendazole-mebendazole, albendazole-oxantel pamoate and mebendazole. Parasites & Vectors 9: 123. doi: 10.1186/s13071-016-1406-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Anderson R.M., Turner H.C., Truscott J.E., Hollingsworth T.D. & Brooker S.J. 2015. Should the goal for the treatment of soil-transmitted helminth STH infections be changed from morbidity control in children to community-wide transmission elimination? PLoS Negl Trop Dis 9(8): e0003897. doi: 10.1371/journal.pntd.0003897 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Truscott J.E., Hollingsworth T.D., Brooker S.J. & Anderson R.M. 2014. Can chemotherapy alone eliminate the transmission of soil transmitted helminths? Parasites & Vectors, 7: 266. doi: 10.1186/1756-3305-7-266 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Anderson R.M., Truscott J.E. & Hollingsworth T.D. 2014. The coverage and frequency of mass drug administration required to eliminate persistent transmission of soil-transmitted helminths. Phil. Trans. R. Soc. B 369: 20130435. doi: 10.1098/rstb.2013.0435 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Clarke N.E., Clements A.C.A., Doi S.A., Wang D., Campbell S.J., Gray D., et al. 2017. Differential effect of mass deworming and targeted deworming for soil-transmitted helminth control in children: a systematic review and meta-analysis. The Lancet 389: 287–297. doi: 10.1016/S0140-6736(16)32123-7 [DOI] [PubMed] [Google Scholar]
  • 35.Bronzan R.N., Dorkenoo A.M., Agbo Y.M., Halatoko W., Layibo Y., Adjeloh P., et al. 2018. Impact of community-based integrated mass drug administration on schistosomiasis and soil-transmitted helminth prevalence in Togo. PLoS Negl Trop Dis 12(8): e0006551. doi: 10.1371/journal.pntd.0006551 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Truscott J.E., Ower A.K., Werkman M., Halliday K., Oswald W.E., Gichuki P.M., et al. 2019. Heterogeneity in transmission parameters of hookworm infection within the baseline data from the TUMIKIA study in Kenya. Parasites & Vectors 12: 442. doi: 10.1186/s13071-019-3686-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Vaz Nery S., Pickering A.J., Abate E., Asmare A., Barrett L., Benjamin-Chung J., et al. 2019. The role of water, sanitation and hygiene interventions in reducing soil-transmitted helminths: interpreting the evidence and identifying next steps. Parasites & Vectors 12: 273. doi: 10.1186/s13071-019-3532-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Anderson R.M. & May R.M. 1991. Infectious Diseases of Humans: Dynamics and Control. Oxford University Press, Oxford, United Kingdom. [Google Scholar]
  • 39.Hardwick R.J., Vegvari C., Truscott J.E. & Anderson R.M. 2019. The ‘breakpoint’ in transmission for soil-transmitted helminths: dynamical behaviour near the equilibria and the impact of infected human migration. bioRxiv 619908.
  • 40.Mascarini-Serra L. 2011. Prevention of soil-transmitted helminth infection. J Glob Infect Dis, 3(2): 175–182. doi: 10.4103/0974-777X.81696 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Midzi N., Montresor A., Mutsaka-Makuvaza M.J., Fronterre C., Manangazira P., Phiri I., et al. 2020. Elimination of STH morbidity in Zimbabwe: Results of 6 years of deworming intervention for school-age children. PLoS Negl. Trop. Dis., 14(10): e0008739. doi: 10.1371/journal.pntd.0008739 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Centers for Disease Control and Prevention. 2019. Guidelines for Overseas Presumptive Treatment of Strongyloidiasis, Schistosomiasis, and Soil-Transmitted Helminth Infections for Refugees Resettling to the United States. https://www.cdc.gov/immigrantrefugeehealth/guidelines/overseas/intestinal-parasites-overseas.html Accessed September 18, 2019.
  • 43.Burkholder D.L. 1978. Point estimation. In: Kruskal W.H. & Tanur J. M. (eds), International encyclopedia of statistics. Free Press, New York, USA, pp. 251–259. [Google Scholar]
  • 44.Walther B.A. & Moore J.L. 2005. The concepts of bias, precision and accuracy, and their use in testing the performance of species richness estimators, with a literature review of estimator performance. Ecography 28: 815–829. doi: 10.1111/j.2005.0906-7590.04112.x [DOI] [Google Scholar]
  • 45.Global Atlas of Helminth Infections. 2019. TUMIKIA project. http://www.thiswormyworld.org/tumikia-project Accessed December 10, 2019.
  • 46.Brooker S.J., Mwandawiro C.S., Halliday K.E., Njenga S.M., Mcharo C., Gichuki P.M., et al. 2015. Interrupting transmission of soil-transmitted helminths: a study protocol for cluster randomised trials evaluating alternative treatment strategies and delivery systems in Kenya. BMJ Open 2015; 5: e008950. doi: 10.1136/bmjopen-2015-008950 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Halliday K.E., Oswald W.E., Mcharo C., Beaumont E., Gichuki P.M., Kepha S., et al. 2019. Community-level epidemiology of soil-transmitted helminths in the context of school-based deworming: Baseline results of a cluster randomised trial in the coast of Kenya. PLoS Negl Trop Dis 13(8): e0007427. doi: 10.1371/journal.pntd.0007427 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.London Centre for Neglected Tropical Disease Research. TUMIKIA: evaluation of school- versus community-based deworming on the transmission of STH in coastal Kenya. https://www.londonntd.org/research/projects-search/tumikia-evaluation-of-school-versus-community-based-deworming-on-the Accessed March 25, 2021.
  • 49.Kenya National Bureau of Statistics. 2015. Kenya Demographic and Health Survey 2014. https://dhsprogram.com/pubs/pdf/fr308/fr308.pdf Accessed October 31, 2019.
PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0009625.r001

Decision Letter 0

Banchob Sripa, Guo-Jing Yang

5 Mar 2021

Dear Dr. Smith?,

Thank you very much for submitting your manuscript "Modelling the ability of mass drug administration to interrupt soil-transmitted helminth transmission: community-based deworming in Kenya as a case study" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers' comments.

We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments, especially please try to translate your results into public health sense so that more audience and understand your performance well. Your revised manuscript is also likely to be sent to reviewers for further evaluation.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Guo-Jing Yang

Associate Editor

PLOS Neglected Tropical Diseases

Banchob Sripa

Deputy Editor

PLOS Neglected Tropical Diseases

***********************

Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: Methods

I am unable to make any comment about the mathematical modelling, but if you are treating worms and of equal importance to public health across species it is flawed as 100 eggs of hookworm cause more morbidity than 100 of T. Trichuria v 100 of Acscaris.

Reviewer #2: (No Response)

Reviewer #3: I think my answer to the above questions is positive. By the way I dont have remarks about.

--------------------

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: Application to the Tumikia project in Kenya

L 269: Is this project aiming to control or to eliminate?

L 274: This sounds as if after 2 years you expect the problem to have been solved without potential recrudescence. Within 2 years you may get reduction or even control (<10% prevalence with <1% moderate/heavy infections) but recrudescence is inevitable of behaviours and WASH resources are not addressed no matter how many rounds of effective drugs are used.

Reviewer #2: (No Response)

Reviewer #3: Yes

--------------------

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: Discussion

L 335: You do not take into consideration that STH eggs remain viable in soil for many years, hence this interruption is only temporary.

L 341 Eradication is a completely new term and not appropriate here. Even elimination is inappropriate. I believe you are aiming for control whilst, WASH and human behavioral changes are strengthened.

Reviewer #2: (No Response)

Reviewer #3: Yes

--------------------

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #1: Author Summary

L 2: I suggest 'control' rather than 'tackle'

L 3: Can you make any comment regarding the cost of using an additional round of weaker drugs vs cost of using stronger drugs and fewer rounds?

Abstract

Responsive to ‘preventive chemotherapy’.

Is the mean number of worms the best way of perceiving the effort to reduce STH to ‘no longer of public health significant’ (<10% prevalence of any STH and <1% moderate/heavy infections) Do you actually mean worms of eggs per gram of faces?

There is such enormous variance in the morbidity of epg by species that you cannot compare 100epg for hookworm with 100epg for Ascaris: the morbidity is grossly different.

Reviewer #2: (No Response)

Reviewer #3: The paper can be published in the present form.

--------------------

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: Introduction

L 12: I suggest 'preventive chemotherapy (PC)' is more appropriate than 'deworming' as one doesn't know if the individual has actually been de-wormed the worm burden will have reduced but whether it gets to zero will depend upon mostly the worm burden before treatment as well as the type of medicine used (more v less effective)

L 18: I don't think 'only' is helpful here as targeted chemo and selective chemo and mass chemo often coexist in a community.

L 19: I don't think you need 'after a regular screening test'. Persons can self-refer for selective chemotherapy and be treated by clinicians/pharmacists without tests and/or buy over the counter medicines without consultations

L 21: Of doses of PC rather than 'treatments'

L 25: This brings be back to my comment about the costs of providing another round of MDA with a less effective agent versus the cost of less rounds of MDA with more effective agents.

L 26: PC should have been introduced earlier and then the abbreviation can be used throughout the manuscript.

L 30: I would add that the strategy needs to be respectful of the local context, traditional authorities, customs and belief systems if the last mile toward STH control is to be effective and that control to be maintained. I suggest that STH recrudesce is almost inevitable if these are not taken into consideration: if personal and environment hygiene are not considered.

L 33: This is a different definition to that used by the WHO 'no-longer of public health significance'

L 34: Important to also mention other important control strategies: improved water and sanitation (WASH).

L 38: Or community-based

L 41: Rather than use the word 'treating' I would use PC

L 44: Trichuris trichiura. The combination of ALB and IVM is recommended for LF-PC.

L 45: T. trichiura

L 48: Only strategy? No health education on WASH and/or efforts to improve safe water and improved sanitation?

L 53: Did this study continue to validate how long before STH recrudesce occurred if there truly was no strategy for WASH?

L 63: Areas with high baseline prevalence are especially in need of health education on personal hygiene and improved sanitation at household, community and school-level. MDA alone will be insufficient to eliminate and prevent resurgence. Rebound STH infection after mass MDA and apparent ‘control’ has been well documented for over 30 years.

L 73: Or consistently don't or cannot adopt improved WASH practices.

L 76: Again you could consider the cost-benefit of this approach, identifying monitoring and treating groups of individual versus improving WASH resources for a community/ or a vulnerable subgroup within a community.

Reviewer #2: The paper presents two mathematical models to guide strategy for MDA as an intervention for STH. The models have been thoroughly investigated, and forecasts for the mean number of worms in the population over time, for different drug efficacies, are presented. The authors investigated different levels of coverage.

The paper does not suit a public health journal. The focus is on the mathematics, and the paper is written with inadequate translation to real life circumstances. The paper reads like an excellent mathematical exercise, but there is a lack of motivation that suits public health readers. For example,

- What is the mean number of worms in a population? The mean of the estimate? The number of worms in a population is a scalar, not a distribution.

- Figure 1 shows the mean value of worms for different R0. There are three lines to correspond to three values of k, without any explanation as to why these values were chosen. The relation of k to the real life is lacking, i.e. it is impossible to interpret what different "clumping parameters of the negative binomial distribution" mean in the real world. What different settings would have a low/high k?

- Why provide the eigenvalues of the models? What does the eigenvalue tell us?

- Lines 116, "Moreover, the endemic equilibrium of model (2) is locally asymptotically stable whenever [an eqn where any relationships between parameters are too complicated to make the eqn easily interpretable] since all associated parameters are positive." What real world information does this tell us about the endemic equilibrium? Similarly on line 216

- L 177 "To find the endpoints of an impulsive orbit..." What is an impulsive orbit? Why do we need to calculate them?

- There is regular mention of choosing arbitrary parameter values. Why? Are real life values impossible to obtain? In which case, why? Because the don't relate to real life or because the data is difficult to obtain?

- How is the drug efficacy interpreted? Is it assuming perfect adherence? Is it the clearance rate?

With regards to writing style - it is unclear what parts of the model are new and the authors contribution to the field.

The application to Kenya data is underwhelming. The prevalence is averaged over the whole country, making the application very broad. It is not shown methodically that only (b) and (c) strategies are considered in this paper. There is a lack of clarity with regards to how many MDA rounds are used in (b) compared to (c). Results are converted from decimals to percentages in an inconsistent manner. The plots are provided without explanation as to the meaning of \\hat{M} etc (plots should be intepretable without having to read the paper).

Abstract

- Don't include parameter notation in the abstract.

- The acronym STH is introduced early on, and then throughout the paper the authors switch from writing out soil-transmitted helminthiasis in full, and using STH.

Main text

- Line 38. The idea of focusing on children is alluded to, but not formally addressed.

- Line 52 How low for R0?

- Line 53 Did Clark et al. [10] use data? This is unclear.

- Line 64 Is MDA the deworming strategy?

- Line 68 states that there is variation in R0. In what sense? Under different settings? This statement doesn't provide enough information to make the reader feel that the work had a conclusion.

- Line 81 to 86 Use the same wording where possible, so that the differences between the two models are immediately clear. Similarly for lines 275-280.

- Line 87-91 and line 212 are missing references to Sections.

- Line 97 needs a reference to justify using a negative binomial distn.

- Table 1 would benefit from z being added, even if stating exp(-\\gamma), to make the introduction to the model smoother.

- The notation M_eq M^* M_* is unclear, and I'm not sure whether the authors interchange parts of these. In general, M^* and M_* are not distinctly different enough.

- Line 125, n is a positive arbitrary integer. What are the units?

- Line 155 states that if k is large. From Fig 1 can you relate this to R0, and instead state that when R0 is large. This is a better reference point because R0 has real life meaning.

- Line 176 What are these functions!?

- For a public health journal, like the abstract, the discussion should avoid use of referring to parameters with their notation (i.e., k).

Reviewer #3: The problem that this manuscript takes in consideration is of great importance in some regions of the world. The authors carry on their analises with the help of some Mathematical models described by ODEs systems. Of special interest is the carefulness that the author put in the derivation of the form of constitutive functions. The numerical results are carefully compared with real data. The author discuss about some possible restrictions on the applicability of their study.The paper is clear and well organized, in my opinion it can be published in the present form.

--------------------

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see https://journals.plos.org/plosntds/s/submission-guidelines#loc-methods

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0009625.r003

Decision Letter 1

Banchob Sripa, Guo-Jing Yang

23 Jun 2021

Dear Dr. Smith?,

Thank you very much for submitting your manuscript "Modelling the ability of mass drug administration to interrupt soil-transmitted helminth transmission: community-based deworming in Kenya as a case study" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. The reviewers appreciated the attention to an important topic. Based on the reviews, we are likely to accept this manuscript for publication, providing that you modify the manuscript according to the review recommendations.

Please prepare and submit your revised manuscript within 30 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to all review comments, and a description of the changes you have made in the manuscript.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Guo-Jing Yang

Associate Editor

PLOS Neglected Tropical Diseases

Banchob Sripa

Deputy Editor

PLOS Neglected Tropical Diseases

***********************

Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: Yes, objectives are clearly articulated and the study design is appropriate with clearly described population and hypothesis. the sample is sufficient and no concerns about ethical regulatory requirements

--------------------

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: Yes

--------------------

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: I think the imitations paragraph needs a little editing:

392: ‘so human-induced interruptions are only temporary; hence our results have less viability in the long term’ could you phrase this. Perhaps something like ‘recrudescence of STH is inevitable without improvements in access to WASH and the adoption of new behaviors by the communities affected’.

L394: and SBCC

L 396-398: could you also include a cost-benefit analysis of these various schedules of MDA. Implementing MDAs takes time, coordination and costs. Volunteers are increasingly expecting to be paid for their services so a more effective drugs delivered less frequently might be significantly cheaper for a health service than a cheaper drug requiring more rounds of MDA.

--------------------

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #1: (No Response)

--------------------

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: This is much improved and now fits better into the reality of programming in SSA. I still have a few comments:

Introduction

L22: ‘deworming’ use instead of ‘PC’ or MDA which is used more often going forward

L24-27: you have omitted the human-element: the change in behavior usually addressed by Social and Behavior Change Communication (SBCC)

L29: you have used PC here but almost everywhere else you have used MDA, please be consistent unless you are trying to differentiate between MDA and PC?

L31: ‘deworming’

L34: and SBCC

L39: now MDA is used instead of PC, please choose on or the other but don’t switch back and forth

L47: Trichuris trichiura has been introduced in full on L46 so it can be abbreviated to T. trichiura form then onwards

L48-49: Schools are not targeted because of cost-efficiencies but because the SAC are, in untreated communities the carriers of the highest burden of STHs and whilst growing suffer the greatest set-backs to growth, health and cognition.

L56: and BCCC (which is different from just health education)

L58: MDA (or PC) but not ‘deworming’

L89: ‘deworming’

L98: presumable also of SBBC?

Discussion:

L373: ‘appropriate’ what is meant by that?

L375: ‘greater than’ or less than?

L375 ‘Otherwise, the infection may persist’ This sounds odd do you mean the infection in that individual or the risk of recrudescence within the community?

--------------------

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Dr Mary H, Hodges

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

References

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article's retracted status in the References list and also include a citation and full reference for the retraction notice.

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0009625.r005

Decision Letter 2

Banchob Sripa, Guo-Jing Yang

5 Jul 2021

Dear Dr. Smith?,

We are pleased to inform you that your manuscript 'Modelling the ability of mass drug administration to interrupt soil-transmitted helminth transmission: community-based deworming in Kenya as a case study' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Guo-Jing Yang

Associate Editor

PLOS Neglected Tropical Diseases

Banchob Sripa

Deputy Editor

PLOS Neglected Tropical Diseases

***********************************************************

Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: (No Response)

**********

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: (No Response)

**********

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: (No Response)

**********

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #1: Line 82 and 369 deworming strategy still there (rather than MDA). In 369 especially it is potentially confusing as the second section specifically refers to MDA.

Line 392 you are now using the term drug administration rather than MDA

**********

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: (No Response)

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Mary H Hodges

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0009625.r006

Acceptance letter

Banchob Sripa, Guo-Jing Yang

28 Jul 2021

Dear Dr. Smith?,

We are delighted to inform you that your manuscript, "Modelling the ability of mass drug administration to interrupt soil-transmitted helminth transmission: community-based deworming in Kenya as a case study," has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: ResponsesToReviewersComments.pdf

    Attachment

    Submitted filename: ResponsesToReviewersComments.pdf

    Data Availability Statement

    All relevant data are within the manuscript.


    Articles from PLoS Neglected Tropical Diseases are provided here courtesy of PLOS

    RESOURCES